9:24 PM
 | 
Oct 24, 2018
 |  BC Extra  |  Preclinical News

Inhibiting metabolic enzyme to prevent NAFLD, acute kidney injury

TES Pharma s.r.l. (Perugia, Italy) is developing small molecule inhibitors of a metabolic enzyme that limits NAD+ production after the metabolic and cancer company and the Swiss Federal Institute of Technology Lausanne (EPFL) showed a new use for blocking it: prevention of non-alcoholic fatty liver disease or acute kidney injury.

Low levels of nicotinamide adenine...

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >